Neuro-Oncology Reviews
Volume
27 Number 14
20 May 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 14, 20 May
Lauwens L, Ribeiro MF, Zegers CML, Høyer M, Alapetite C,
Blomstrand M, Calugaru V, Perri DD, Iannalfi A, Lütgendorf-Caucig
C, Paulsen F, Postma AA, Romero AM, Timmermann B, Troost EGC, van
der Weide HL, Whitfield GA, Harrabi S, Lambrecht M, Eekers DBP.
Systematic review of MRI alterations
in the brain following proton and photon radiation therapy:
Towards a uniform European Particle Therapy Network (EPTN)
definition.
Radiother
Oncol. 2025 May 11;208:110936. doi:
10.1016/j.radonc.2025.110936. PMID:
40360047. Review˰ ˍ
Politis A, Stavrinou L, Kalyvas A, Boviatsis E, Piperi C.
Glioblastoma: molecular features,
emerging molecular targets and novel therapeutic strategies.
Crit
Rev Oncol Hematol. 2025 May 12:104764. doi:
10.1016/j.critrevonc.2025.104764. PMID:
40368035. Review˰ ˍ
Pu J, Yuan K, Tao J, Qin Y, Li Y, Fu J, Li Z, Zhou H, Tang Z, Li
L, Gai X, Qin D.
Glioblastoma
multiforme: an updated overview of temozolomide resistance
mechanisms and strategies to overcome resistance.
Discov
Oncol. 2025 May 12;16(1):731. doi:
10.1007/s12672-025-02567-3. PMID:
40353925. Review. ˍ
Qu M, Wang Q, Wang X, Tang J, Dong X, Zhao C, Guan Q.
Recent
advances in nanomaterial-based brain-targeted delivery systems for
glioblastoma therapy.
Nanomedicine
(Lond). 2025 May 12;20(12):1495-1511. doi:
10.1080/17435889.2025.2503694. PMID:
40353316. Review˰ ˍ
Kisby T, Borst GR, Coope DJ, Kostarelos K.
Targeting
the glioblastoma resection margin with locoregional
nanotechnologies.
Nat
Rev Clin Oncol. 2025 May 14. doi:
10.1038/s41571-025-01020-2. PMID:
40369318. Perspective˰
ˍ
Ghosh N, Chatterjee D, Datta A.
Tumor
heterogeneity and resistance in glioblastoma: the role of stem
cells.
Apoptosis.
2025 May 15. doi:
10.1007/s10495-025-02123-y. PMID:
40375039. Review. ˍ
Luo C, Zhang F, Zhu X, Zeng Y, Wang Z, Jiang H, Ye Q, Jian W,
Zhang J, Fu Q.
Multifocal
medulloblastoma in an adult: a case report and review of the
literature.
J
Cancer Res Clin Oncol. 2025 May 15;151(5):166. doi:
10.1007/s00432-025-06215-9. PMID:
40369375. Case report; Review. ˍ
Beichert J, Hoffmann DC, Winkler F, Ratliff M.
Innovative
Therapeutic Strategies Targeting the Network Architecture of
Glioblastoma.
Clin
Cancer Res. 2025 May 16. doi:
10.1158/1078-0432.CCR-25-0018. PMID:
40378061. Review. ˍ
Kendall N, Rechberger JS, Hamouda AM, Cwajna M, Ghozy S,
Arumaithurai K, Kallmes DF.
Assessing
compliance to reporting mandates in glioblastoma-related clinical
trials.
PLoS
One. 2025 May 16;20(5):e0323109. doi:
10.1371/journal.pone.0323109. PMID:
40378099. Regulations. ˍ
Li Y, Qu S, Zuo J, Long H, Cao F, Jiang F.
Progress
on the functions and mechanisms of natural products in anti-glioma
therapy.
Chin
J Nat Med. 2025 May 16;23(5):541-559. doi:
10.1016/S1875-5364(25)60815-6. PMID:
40383611. Review˰ ˍ
Riyas Mohamed FR, Yaqinuddin A.
Epigenetic
reprogramming and antitumor immune responses in gliomas: a
systematic review.
Med
Oncol. 2025 May 16;42(6):213. doi:
10.1007/s12032-025-02760-y. PMID:
40380049. Review˰ ˍ
Wang H, Bian C, Zhang Y, Zhang L, Wang F.
Circular
RNAs in glioma progression: Fundamental mechanisms and therapeutic
potential: A review.
Int
J Biol Macromol. 2025 May 17;313:144360. doi:
10.1016/j.ijbiomac.2025.144360. PMID:
40388873. Review˰ ˍ
Golab F, Hajimirzaei P, Zarbakhsh S, Zolfaghari S, Hayat P,
Joghataei MT, Bakhtiarzadeh F, Ahmadirad N.
Interplay
of Neuroinflammation and Epilepsy in Glioblastoma Multiforme:
Mechanisms and Therapeutic Implications.
J
Mol Neurosci. 2025 May 20;75(2):68. doi:
10.1007/s12031-025-02335-6. PMID:
40392361. Review˰ ˍ
Hekim S, Bunda S, Dilibaerguli S, Palihati M, Mamatjan Y.
HOX
gene dysregulation in glioblastoma: a narrative review of current
advances.
Discov
Oncol. 2025 May 20;16(1):828. doi:
10.1007/s12672-025-02684-z. PMID:
40392454. Review. ˍ